KOSPIBiotech & Pharma025620

CHA AI Healthkare

₩4,855 0.00%2026-11-18 close
Market Cap
₩88.4B
Turnover
₩22,027,860
Volume
4.6K
Shares out.
18.2M
PER
27.3×
PBR
1.2×
EPS
₩180
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

From cosmetics maker toward AI healthcare affiliate

CHA AI Healthkare swung to a net profit attributable to controlling shareholders in 2025, but returned to a net loss in the third quarter of 2026, so the durability of its profit is the next test.

  1. 1

    Revenue peaked at KRW 17 billion in 2023, then fell two years running to KRW 15.7 billion in 2024 and KRW 7.31 billion in 2025.

  2. 2

    The 2025 swing to a KRW 1.37 billion profit attributable to controlling shareholders came alongside a widened operating loss of KRW 7.46 billion, extending a four-year run of operating losses.

  3. 3

    Net profit attributable to controlling shareholders of KRW 10.4 billion in the second quarter of 2026 exceeded that quarter's operating loss of KRW 1.13 billion, suggesting non-operating items made up much of the result.

  4. 4

    Third-quarter 2026 revenue fell 48.0% from the prior quarter to KRW 1.51 billion, and the net loss attributable to controlling shareholders was KRW 7.04 billion.

  5. 5

    Equity-method losses from the Kakao Healthcare stake and the KRW 40 billion 36th convertible bond are cited as financial and share-supply variables.

02

Business structure

CHA AI Healthkare was founded in 1972 and added a cosmetics manufacturing and sales business in 2016, with sheet masks and basic skincare as its core products.

At the end of 2025 it changed its name from Jayjun Cosmetic to CHA AI Healthkare, linking its existing consumer touchpoints in beauty and wellness to the group's digital healthcare strategy.

Within the group, CHA AI Healthkare handles data and AI technology development, while a group subsidiary handles the practical operation of hospitals and medical facilities.

CHA AI Healthkare and that subsidiary jointly hold the Kakao Healthcare stake; according to media reports, CHA AI Healthkare held 36.58% and the two together held 83.61% at the end of 2025. In November 2025 CHA AI Healthkare said it would take part in a KRW 10 billion rights offering at Kakao Healthcare, a 10.5% stake.

CHA AI Healthkare holds Kakao Healthcare as an associate and reflects its equity-method gains and losses. On the product side, in March 2026 it signed a supply contract for Green Tea Eye Gel Patches for the United States and Mexico, worth a little over KRW 1.2 billion, equal to 7.99% of 2024 revenue.

At the group level, the parent group said in November 2025 that it operated 77 medical platforms across 11 cities in 6 countries, and that hospital network is cited as a route for expanding the AI services.

In competition, media analysis points out that medical data processing, AI model development and hospital operations each involve different regulatory environments and expertise, making integration an early challenge.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.6B-₩2.1B−130.8%
2025Q4₩2B-₩2B−102.2%
2026Q1₩1.9B-₩2.4B−122.4%
2026Q2₩2.9B-₩1.1B−39.0%
2026Q3₩1.5B-₩1.6B−108.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩6.2B-₩10.7B-₩21.4B−170.8%−51.5%16.4%
2023₩17B-₩10.2B-₩6.8B−59.8%−17.0%20.9%
2024₩15.7B-₩5.4B-₩9.5B−34.7%−32.0%31.3%
2025₩7.3B-₩7.5B₩1.4B−102.1%1.8%46.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

Annual revenue rose from KRW 6.25 billion in 2022 to KRW 17 billion in 2023, a 172.7% increase, and then fell 8.0% to KRW 15.7 billion in 2024 and 53.4% to KRW 7.31 billion in 2025. Media reports attributed the 2025 revenue decline mainly to a change in the business structure.

The operating loss narrowed from KRW 10.7 billion in 2022 to KRW 10.2 billion in 2023 and KRW 5.45 billion in 2024, then widened to KRW 7.46 billion in 2025. The operating margin improved from -170.8% in 2022 to -34.7% in 2024 before deteriorating to -102.1% in 2025.

Net loss attributable to controlling shareholders was KRW 21.4 billion in 2022, KRW 6.8 billion in 2023 and KRW 9.49 billion in 2024, before the company swung to a KRW 1.37 billion profit in 2025. Net profit including non-controlling interests was also KRW 1.37 billion in 2025.

Because the operating loss widened in 2025 while the bottom line turned positive, the profit depended on items below the operating line, which media reports tied to gains on derivative valuation.

At the end of 2025, total equity was KRW 75.4 billion, all of it attributable to controlling shareholders, and total liabilities were KRW 34.8 billion. The debt-to-equity ratio rose from 16.4% in 2022 to 46.2% in 2025.

Operating cash flow was negative every year, at -KRW 4.98 billion in 2022, -KRW 9.86 billion in 2023, -KRW 6.91 billion in 2024 and -KRW 6.71 billion in 2025.

Quarterly revenue went from KRW 1.63 billion in the third quarter of 2025 to KRW 1.96 billion in the fourth quarter, which was up 20.7% from the prior quarter, then KRW 1.94 billion in the first quarter of 2026 and KRW 2.91 billion in the second quarter, before falling 48.0% to KRW 1.51 billion in the third quarter of 2026.

Quarterly operating losses have run for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026, ranging from KRW 1.13 billion to KRW 2.37 billion.

Net profit attributable to controlling shareholders was KRW 4.56 billion in the fourth quarter of 2025 and KRW 10.4 billion in the second quarter of 2026, and was a loss in the other three quarters.

In the second quarter of 2026 the profit was far larger than that quarter's operating loss, which points to a large non-operating contribution. Over the last four quarters, net profit attributable to controlling shareholders totaled KRW 3.28 billion, and the swings between quarters are too large to read as a trend.

05

Industry analysis

The market CHA AI Healthkare operates in splits into two parts. In cosmetics, a corporate monitoring analysis says revenue rose in the first quarter of 2026 on domestic channel diversification and overseas expansion, but a lower gross margin and higher costs widened the operating loss.

In healthcare, the AI-based digital healthcare business is in an expansion phase, and its revenue base is still small. Kakao Healthcare was reported to have posted first-quarter 2026 revenue of KRW 6.8 billion, an operating loss of KRW 10.1 billion and a net loss of KRW 10.2 billion.

That loss flowed through to CHA AI Healthkare as an equity-method loss, which media reports put at about KRW 3 billion in the first quarter of 2026.

The parent group's first-half 2026 disclosure showed consolidated revenue of KRW 646.1 billion and an operating loss of KRW 58.9 billion, with the company citing AI-based digital healthcare expansion and advanced regenerative medicine R&D as the main causes.

In competitive position, CHA AI Healthkare's strength is cited as combining data and AI capability with the group's hospital infrastructure. Its own revenue base, at KRW 7.31 billion in 2025, is small, which makes outside partnerships important.

In January 2026 LG CNS agreed to invest KRW 10 billion in the parent and to pursue AI-based connected healthcare services with the group. In cosmetics, overseas supply contracts serve as a gauge, and the March 2026 contract for the United States and Mexico is one example.

06

Outlook

The business direction of CHA AI Healthkare is being set within the group's connected healthcare strategy. The group aims to link its hospital network with data, AI and platforms into one service flow, and analysts say this direction has gained momentum since the Kakao Healthcare acquisition.

If the hospital operating infrastructure of the subsidiary and the technology capability of CHA AI Healthkare link with the Kakao Healthcare platform, expansion of integrated services such as data-based care and AI prognosis prediction is expected.

According to media reports, at the end of 2025 Kakao Healthcare's ownership was 47.03% held by the subsidiary, 36.58% by CHA AI Healthkare and 16.39% by Kakao. The KRW 40 billion 36th convertible bond issued by CHA AI Healthkare funded the Kakao Healthcare investment and has been convertible since October 29, 2026.

Analysts note that if the share price exceeds the conversion price, dilution and selling pressure could grow, while below it the possibility of early redemption requests stands out.

On December 11, 2026, 9,724,473 common shares will be released from lock-up, equal to 53.4% of the total issued shares at the end of the first quarter.

At group level, the parent said in its first-half 2026 disclosure that it is expanding investment in future growth businesses such as AI-based digital healthcare and advanced regenerative medicine.

In the 2026 annual report, the next periodic filing, annual revenue, operating loss, net profit attributable to controlling shareholders and equity-method results from Kakao Healthcare will be confirmed together.

07

Valuation

PER
27.3×
PBR
1.2×
ROE
5.9%
EPS
₩180
BPS
₩4,066
Dividend per share
₩0

On the current multiple, the company's earnings base is small relative to its market value when measured against the KRW 3.28 billion net profit attributable to controlling shareholders over the last four quarters.

The 2025 figure of KRW 1.37 billion is a swing from a 2024 net loss, so the earnings base is short and the range of multiple interpretation is wide. On net assets, the share price sits at a premium to total equity. The dividend yield is effectively zero, so the shareholder return from dividends is small.

Factors that could move the share price include quarterly swings in net profit, conversion of the convertible bond, and the lock-up release schedule. Because profit and loss alternated between quarters within 2026, the earnings base used in the multiple changes sharply from quarter to quarter.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Signs of an earnings turn

Net profit attributable to controlling shareholders swung from a KRW 9.49 billion loss in 2024 to a KRW 1.37 billion profit in 2025. The second quarter of 2026 also posted a KRW 10.4 billion profit attributable to controlling shareholders, showing that quarterly profit has occurred.

Over the last four quarters the total was KRW 3.28 billion, and bulls cite the swing from losses to profit as the core evidence.

Group digital healthcare synergy

Analysts say that if the subsidiary's hospital infrastructure and CHA AI Healthkare's data and AI technology link with the Kakao Healthcare platform, the scope for data-based healthcare services widens. The parent also agreed a data platform partnership with LG CNS.

Because the hospital network spans several countries, it could serve as a route for connected healthcare services.

Cosmetics channel expansion and overseas supply

A corporate monitoring analysis says cosmetics revenue rose in the first quarter of 2026 on domestic channel diversification and overseas market development. Second-quarter 2026 revenue reached KRW 2.91 billion, up 50.1% from the prior quarter. A March 2026 supply contract for the United States and Mexico added an overseas sales track record.

09

Bear factors

Continued revenue contraction

Revenue fell two years running, from KRW 17 billion in 2023 to KRW 15.7 billion in 2024 and KRW 7.31 billion in 2025. Media reports tied the 2025 decline mainly to a business structure change. Third-quarter 2026 revenue fell 48.0% from the prior quarter and 7.0% from a year earlier.

Wider and prolonged operating losses

The operating loss widened to KRW 7.46 billion in 2025 from KRW 5.45 billion in 2024, and the 2025 operating margin was -102.1%. Operating losses have run for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026.

The third-quarter 2026 operating loss of KRW 1.64 billion widened again from KRW 1.13 billion in the second quarter.

Equity-method losses and convertible bond overhang

Because Kakao Healthcare continues to post losses, media reports say CHA AI Healthkare booked an equity-method loss of about KRW 3 billion in the first quarter of 2026. The KRW 40 billion 36th convertible bond could weigh on the share supply.

The third-quarter 2026 net loss attributable to controlling shareholders was KRW 7.04 billion, and the debt-to-equity ratio reached 46.2% at the end of 2025.

10

Risk factors

Financial and equity risk

The KRW 40 billion 36th convertible bond has been convertible since October 29, 2026, and depending on the share price could bring dilution or early redemption requests. On December 11, 2026, 9,724,473 common shares come off lock-up, equal to 53.4% of total issued shares at the end of the first quarter.

Associate performance risk

Losses at Kakao Healthcare flow through to CHA AI Healthkare's results as equity-method losses. If Kakao Healthcare's reported first-quarter 2026 operating loss of KRW 10.1 billion reflects a continuing pattern, equity-method losses could recur.

Commentary also points to likely clashes in work methods and development systems across data processing, AI development and hospital operations.

Quarterly earnings volatility risk

With 2025 revenue at KRW 7.31 billion, quarterly revenue has moved between about KRW 1.5 billion and KRW 2.9 billion, so quarterly results swing widely. Net profit attributable to controlling shareholders was KRW 10.4 billion in the second quarter of 2026 and a KRW 7.04 billion loss in the third quarter. A lower gross margin in cosmetics has also added to cost pressure.

11

What to watch next

  1. Ongoing from November 2026

    Conversion requests on the 36th convertible bond and where the share price sits relative to the conversion price. Conversions would increase the share count and dilute existing holders.

  2. December 11, 2026

    Release of 9,724,473 common shares from lock-up, equal to 53.4% of total issued shares, a date cited as a possible source of selling supply.

  3. By March 31, 2027

    Filing of the 2026 annual report, the next periodic filing, which will show annual revenue, operating loss, net profit attributable to controlling shareholders and equity-method results from Kakao Healthcare together.

12

Overall view

CHA AI Healthkare posted operating losses every year from 2022 through 2025, and revenue fell from a peak of KRW 17 billion in 2023 to KRW 7.31 billion in 2025.

The 2025 swing to a KRW 1.37 billion profit attributable to controlling shareholders came while the operating loss widened to KRW 7.46 billion, so whether that profit came from non-operating items needs continued checking.

Quarterly results have also alternated, with a KRW 10.4 billion profit in the second quarter of 2026 and a KRW 7.04 billion loss in the third quarter. The last four quarters totaled KRW 3.28 billion.

Equity-method losses from Kakao Healthcare, the KRW 40 billion convertible bond and the December 11, 2026 lock-up release are the financing and share-supply variables.

Bullish factors include group digital healthcare synergy and cosmetics channel expansion, while bearish factors include shrinking revenue and a continuing operating loss. The next checkpoint is the operating loss and equity-method results in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. seoultimes.news
  2. koreadaily.com
  3. comp.wisereport.co.kr
  4. healtho.co.kr
  5. m.news.nate.com
  6. bloter.net
  7. theguru.co.kr
  8. investing.com
  9. m.news.nate.com
  10. dealsite.co.kr
  11. m.news.nate.com
  12. newstomato.com
  13. ajunews.com
  14. thebionews.net
  15. news.nate.com
  16. ngonews.kr
  17. fintechtimes.co.kr
  18. m.news.nate.com

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis